Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. - Wikidata - awgldk - TriplyDB

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

http://www.wikidata.org/entity/Q37392767

about

Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins Current treatment of atypical mycobacteriosis Assessment of treatment response in tuberculosis Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis Virulence of Mycobacterium tuberculosis after Acquisition of Isoniazid Resistance: Individual Nature of katG Mutants and the Possible Role of AhpC Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.The chemotherapy of tuberculosis: past, present and future.Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model Serum drug concentrations predictive of pulmonary tuberculosis outcomes.The antifibrotic drug pirfenidone promotes pulmonary cavitation and drug resistance in a mouse model of chronic tuberculosis.Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria.Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.Assessing Pharmacodynamic Interactions in Mice using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models.

P2860

Q27700967-AC1039E1-032F-4883-BC49-32929D01D4E7 Q28265322-7885540F-3E71-4382-87DE-02DE1171962F Q28384421-C7D8CC32-9D05-460F-9A89-AE89205A9E52 Q28539383-5684AFA1-6C61-4D38-9621-7779A0FA5C3E Q28540482-FD1A767F-35A7-4966-8E37-7EF82E03AF14 Q28554450-15174ED3-D09E-41FD-BE73-123BA85B55BD Q30421576-2A8C193D-8E32-4122-A189-A17FD8D64A3B Q33589762-55B71749-53B5-4678-9DF3-E6783DEC92CF Q33621748-77B77F9B-A3C1-439D-B475-6AB0018EB8B1 Q34092117-AC037BDC-8571-4020-991D-F4A9BFD89042 Q34708437-E3E6BDD1-524B-49D3-BAFD-8938AFD996B9 Q34737143-25B55D7C-BD17-4069-934E-04E960DEF2B0 Q34737913-70438D95-586D-40D8-BCBB-C4009D609D67 Q34922554-59F583A4-55B0-4F5B-A1FB-41037BD2C3A4 Q34981779-72638565-F217-4F33-BC54-A83A30D128D3 Q35042502-0250E4F2-06DE-4EA1-909E-AC4F7E5A7D45 Q35076966-067A067A-FC58-4DF5-96AD-3E974CAA9B6A Q35527885-138BEE1A-C309-4F28-9221-D247B82BF26D Q35878689-BDD34A7D-E098-4B3E-8AAE-CEF7AFEBEEB1 Q36171524-373ACAFF-ED6D-4D56-9AA1-DA79E2B69467 Q36236341-5BFA4B39-67E7-403F-ADE9-5301FC9B077D Q36290586-D6FB01BC-BD95-4DF3-99F0-74EF5864293C Q36571928-675E188E-4446-4337-A1AC-C8AF07060F2B Q36613180-0808E54F-2341-4EC4-A270-37DD05709B66 Q36821344-BCCD9FD4-EFE8-42AD-A232-037FC66078CE Q37074826-CCC8B86E-4508-4818-9FD0-D10F92836DFC Q37076746-9BF1EF7B-52A3-44C4-9359-8CB6B49C20CC Q37119985-FE632BFC-572F-4FC3-90E5-E978769EBA1D Q37213037-8E57DB7C-01AD-4199-9E9A-6F9A07C1B1B8 Q37277346-46473B02-9DB1-487A-B630-10D2A23B9E6D Q37306561-58C17B8A-2691-457C-A2D6-01617F1B6C0E Q37307531-E93FCF85-AE59-4A76-9910-DA24F5ACDA7E Q37339268-8E165EC5-D576-464C-B307-E82E8C0C052A Q37339276-007A305C-D316-4128-B5AF-01FEFA6DE2D2 Q37339294-2888A135-AC3A-4E7E-B6F6-07312B234F34 Q38368943-AC7D2B61-E92E-42E1-81CA-EC708022D55D Q38502298-C989A6D5-1F11-44DB-A9AF-E1A4179602F1 Q38754367-4F90A3FD-0449-4432-B13D-776AC8FD8A37 Q40065997-2ED32479-D73A-472C-88CE-51BC424D4748 Q40155324-E4041C19-0636-4810-B761-CAAA06D3A258

P2860

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

http://www.wikidata.org/entity/Q37392767

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.

@en

Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.

@nl

type

label

Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.

@en

Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.

@nl

prefLabel

Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.

@en

Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.

@nl

P1433

Q37392767-4EF0B981-A5C6-4433-9E3E-379DC73A6542

P1476

Q37392767-D7ED0F5F-8118-43F7-8250-D35CD51BC178

P2093

Q37392767-32F373E4-ACD5-4CE3-9A3F-EFF5EEF74DDE

Q37392767-490CA0C6-E53B-49BF-A9A0-07305C7F2211

Q37392767-572EA3AA-CC1F-4537-8ED6-27BEE75A03A7

Q37392767-78E04DF0-5053-4B3A-8A41-D03E4314F2AF

Q37392767-91125D4B-85D1-4865-B23C-19F017F593CA

Q37392767-C14242E4-673C-448E-B488-E75584686843

Q37392767-CED8745D-6C60-44AE-96E2-0BE42C582DE9

Q37392767-DEE646A1-CAB6-407F-8D38-05D6E1CBC72F

P2860

Q37392767-0AEEF039-3338-4F21-AD80-CB61B71B5329

Q37392767-11A4A240-A42B-4BF6-A046-5BE7A7AD704D

Q37392767-19D1FFF2-0AD3-4DEF-B089-AE6CA5520E9D

Q37392767-1AC9E63D-3C35-4488-80B8-59747B33DBF3

Q37392767-64116745-48CF-4BF8-9D92-6622421AA674

Q37392767-715D0A33-7FBF-4221-B41B-A48B71151602

Q37392767-7D7423A3-47CA-4B2F-B46B-3D7742321536

Q37392767-805A78CB-50BB-4A74-9CFD-1849E57EE79C

Q37392767-8F230724-BD2E-4709-87A7-66A5D5A0774A

Q37392767-B1C71CDB-3175-4F95-8534-7E1D898256EE

P304

Q37392767-6CB78645-772B-444F-BD9C-E80301BA3680

P31

Q37392767-4F1B0C55-1799-44C6-BE8B-3AB8D109A6D5

P356

Q37392767-FEC0C767-1A09-4C58-8FE4-F82057ECFAEC

P407

Q37392767-8E2C0471-66F4-47F3-BABC-7BFEA379377B

P433

Q37392767-65192FA5-F89F-420F-B38E-DB0B6AE6ED7F

P478

Q37392767-49109D88-BADA-4D1E-9121-9B4DB14FFB64

P577

Q37392767-A0B449A0-8943-4E6A-9B12-8457A616F191

P698

Q37392767-28BEA2AF-AEC2-4347-B8A3-F9EC7BA89A78

P921

Q37392767-A6D40DA2-44B9-4292-9C5A-5EE6D5E0FE2F

P932

Q37392767-C3895669-569B-4A40-ABB3-2CFB2B9909C7

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Paradoxical effect of isoniazi ...... a mouse model of tuberculosis.

@en

P2093

Charles Peloquin

http://www.w3.org/2001/XMLSchema#string

Deepak Almeida

http://www.w3.org/2001/XMLSchema#string

Eric Nuermberger

http://www.w3.org/2001/XMLSchema#string

Ian Rosenthal

http://www.w3.org/2001/XMLSchema#string

Jacques Grosset

http://www.w3.org/2001/XMLSchema#string

Kathy Williams

http://www.w3.org/2001/XMLSchema#string

Rokeya Tasneen

http://www.w3.org/2001/XMLSchema#string

Sandeep Tyagi

http://www.w3.org/2001/XMLSchema#string

P2860

Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

The curious characteristics of pyrazinamide: a review

The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

The chemical approach to the control of tuberculosis.

Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.

P304

4178-4184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00830-09

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19620331

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2764177

http://www.w3.org/2001/XMLSchema#string